TAM receptors (Tyro3, Axl and Mer) belong to a family of Receptor Tyrosine Kinases that have important effects on hemostasis and inflammation. Also, they affect cell proliferation, survival, adhesion and migration. TAM receptors can be activated by the vitamin K-dependent proteins Gas6 and protein S. Protein S is more commonly known as an important co-factor for protein C, as well as a direct inhibitor of multiple coagulation factors. To our current knowledge the functions of Gas6 are limited to TAM receptoractivation. When activated, the TAM receptors have effects on primary hemostasis and coagulation, and they display an anti-inflammatory or a pro-inflammatory effect, depending on cell-type. To comprehend the effects that the TAM receptors and their ligands have on hemostasis and inflammation, we compare studies that report the different phenotypes displayed by mice with deficiencies in the genes of this receptor family and its ligands (protein S +/-, Gas6 -/-, TAM -/-, and variations to these). In this manner we aim to display which features are attributable to the different ligands. Because of the effects the TAM receptors have on hemostasis, inflammation and cancer growth, their modulation could make interesting therapeutic targets in thrombo-embolic disease, atherosclerosis, sepsis, autoimmune disease and cancer.
Introduction
In recent years, views on hemostasis and inflammation have shifted from a concept of two independent areas of biology, towards two closely related processes. It is now appreciated, that molecules that affect hemostasis often have an effect on inflammation and vice-versa. In this review we explore this dual role for Gas6, protein S and TAM receptors.
The TAM receptors are one of 20 subfamilies of Receptor Tyrosine Kinases (RTKs). 1 First cloned in 1991, they were considered orphan receptors until 1995. 2 In that year their ligands, protein S and Growth Arrest-Specific gene 6 (Gas6), were identified. [3] [4] [5] Members of the TAM receptor family are Tyro3 (also called Brt, Dtk, Etk-2, Rek, Rse, Sky, Tif), Axl (also called Ark, Tyro7, Ufo) and Mer (also called c-Eyk, Mertk, Nyk, Tyro12).
TAM receptors are composed of two immunoglobulin-like and two fibronectin Type III repeats in their extracellular domains, in tandem. This is connected to a single pass
For personal use only. on May 30, 2017 . by guest www.bloodjournal.org From transmembrane domain and a cytoplasmatic protein tyrosine kinase (Fig. 1A) . Upon ligand binding, the receptor dimerizes and the tyrosine kinase becomes activated. 6 In recent years, several signaling functions of the TAM receptors have been described, such as stimulation of cell growth and proliferation, inhibition of apoptosis 7, 8 , mediation of efferocytosis 9 , stimulation of hemostasis 10 and modulation of inflammation 11 . In this review we will focus on the functions of the TAM receptors pertaining to hemostasis and inflammation. When activated by Gas6, the TAM receptors stimulate hemostasis by facilitating platelet stabilization. 10 The other ligand, protein S, has a TAM-independent inhibitory effect on hemostasis. [12] [13] [14] Activation of the TAM receptors was found to inhibit TLR signaling, to induce phagocytosis and stimulate natural killer cell development,
leading to speculations about a role in preventing auto-immunity.
This review delineates the known functional similarities and differences between protein S, Gas6 and the TAM receptors. The recently described knock-out mice for protein S, Gas6 and the individual TAM receptors have strongly contributed to the new insights in this field. By comparing the phenotypes of the different knock-out mice, we discuss the functions of protein S that are attributable to TAM receptor activation and those functions that are the effect of protein S alone.
Protein S
Protein S is a vitamin K-dependent protein encoded by the PROS1 gene in humans and by Pros1 in mice. Unlike genes encoding for most vitamin K-dependent factors, the PROS1 gene is also expressed in other tissues than the liver: transcription of PROS1 can be found in the kidney, lungs or gonads. Protein S is produced by a variety of cell types, e.g. hepatocytes, endothelial cells, megakaryocytes and osteoblasts. 15 It contains an amino terminal GLA domain, followed by a thrombin-sensitive loop region and four EGF-like domains ending with the C-terminal, consisting of two laminin G repeats, that together comprise the sex-hormone-binding globulin domain (Fig. 1B) . 16 The carboxyterminal region is sufficient for TAM-receptor binding and phosphorylation. 17 Protein S circulates in plasma at a concentration of 346 nmol/L 18 and serves as an anticoagulant by working as a non-enzymatic co-factor for activated protein C in the breakdown of coagulation factors FVa and FVIIIa. 12 It is further capable of binding FXa
For personal use only. on May 30, 2017 . by guest www.bloodjournal.org From and FVa directly, whereby it can autonomously inhibit coagulation. 13, 14, [19] [20] [21] Factor Xa is also inhibited by protein S through acting as a co-factor for tissue factor pathway inhibitor (TFPI). 22 In humans, it exists in a free active form (30-40%) and in an (almost) inactive form, bound to C4b-binding protein (60-70%). 23 It is therefore plausible, that in humans protein S is apt to affect the complement system. 24 In mice, however, protein S only exists in its free form, because the murine C4b-binding protein lacks the β-chain, which is essential for binding protein S. 25 The functional consequences of this difference remain unknown.
Heterozygous deficiency of PROS1 is associated with an elevated risk for developing thrombosis, 26, 27 whereas homozygous deficiency is incompatible with life or leads to neonatal purpura fulminans in rare cases. 28 Lastly, protein S has been identified as a ligand for the TAM receptors in addition to Gas6. It has been shown capable of binding Tyro3, e.g. in osteoclasts. 29 In retinal pigment epithelium protein S has been described to be equally important and interchangeable with
Gas6 in vivo as a Mer ligand. 30 Affinity between protein S and Axl, however, has never been shown. Protein S binding to Tyro3 and Mer shows a high degree of species specificity. Peculiar is that human protein S shows only weak or no affinity for the different human TAM-receptors, while bovine protein S displays good affinity to human Tyro3 (reviewed by Hafizi 31 ).
Gas6
Gas6 is a 75 kDa vitamin K-dependent protein, first discovered under conditions of growth arrest in embryonic mouse NIH 3T3 fibroblasts. 32, 33 It has high structural homology (~42%) with protein S and the modular composition is the same (as described above and shown in Fig. 1B ). Unlike in protein S, the thrombin-sensitive region in Gas6
(a disulfide-bridged thumb loop) does not seem to be susceptible to cleavage by the action of serine proteases. The concentration of Gas6 is around 20-50 ng/mL (0.25 nmol/L) in plasma, and elevated to about 110 ng/mL in severe sepsis patients. 34, 35 These levels are much lower than those of the other vitamin K-dependent proteins of plasma.
Another difference with other vitamin K-dependent proteins is that Gas6 is barely produced in the liver, but rather in heart, kidneys and lungs. Important tissues where Gas6 
TAM receptors
Expression of the individual TAM receptors can be found in many cell types, but the patterns vary. Tyro3 is mostly found in the central nervous system, kidneys, ovaries and testes. 41, 42 Axl is nearly ubiquitously expressed in most human cells originating from hematopoietic, epitelial and mesenchymal sources. 43 Mer is predominantly expressed in ovaries, testes, prostate, lungs and kidneys and to a lesser extent in the thymus, spleen, liver, small intestine, colon and placenta. 44, 45 Important cell types in which TAM receptors are active are e.g. antigen-presenting cells, 46 monocytes and natural killer cells in the immune system, 44 osteoclasts in bone, 28 Sertoli cells in the testis, 47 endothelial cells and vascular smooth muscle cells in the vasculature, 48 and pigmental epithelium cells in the retina. 49 In contrast, they are not expressed in granulocytes or blood lymphocytes. 50 In tumor cells TAM-receptors are often up-regulated (reviewed by Linger 51 ).
Along with this wide expression of TAM receptors, many functions can be described.
This review will not discuss all of these functions, but will focus on hemostasis and inflammation.
With respect to hemostasis, all three TAM receptors are located on platelets and mediate thrombogenesis and platelet stabilization. Platelet stabilization occurs after integrin activation, granule secretion and platelet aggregation, through platelet-to-platelet contact.
Without this mechanism, platelet plugs disaggregate prematurely (reviewed by Prevost 52 (Fig. 2) . 10, 39 Also, vascular Gas6 up-regulates tissue factor in vascular cells when vessel injury occurs, leading to activation of the extrinsic coagulation pathway and thrombus formation. 53 Gas6 is released from mouse platelets, 37, 38 but human platelets do not seem to contain Gas6. 34, 35 Besides, only expression of the Mer receptor on human platelets has been shown. 54 Still, Gas6 levels in plasma were higher in patients with venous thromboembolic disease, as compared to healthy volunteers. 55 Also, genetic evidence shows an association between certain single nucleotide polymorphisms in the GAS6 gene and stroke, 56 
39,60
Protein S is upregulated by IL-4 in primary T-cells. 61 Natural killer T cells require Mer to induce the transcription of IL-4 and IFN-γ. 62 Whether this results in a feed-back loop in vivo is unknown. A cell-proliferative function of TAM signaling that aids inflammation is induced differentiation in the maturation process of natural killer cells. 63 Similarly in the kidney, activation of Axl promotes inflammation through increased proliferation of mesangial cells. 64 In contrast to supporting the inflammatory response as described above, TAM receptor signaling inhibits inflammation by multiple mechanisms. Activation of Mer, in contrast
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TNF-α). 11 Activation of cytokine receptors leads to an IFNAR/STAT1 upregulation of Axl (Fig. 3) . Together with the IFNAR/STAT1 signaling cassette, the TAM receptors induce the transcription of the anti-inflammatory SOCS1 and SOCS3, and inhibit both cytokine receptors and TLR signaling pathways. 66, 67 The decreased expression of these anti-inflammatory mediators in TAM -/-cells seems to point to a crucial role of SOCS proteins in the anti-inflammatory action of TAM receptors. However, a direct dependence of TAM anti-inflammatory function on SOCS has not yet been proven. TAM activation also induces Twist transcriptional repressors that suppress nuclear factor-κB (NFκB)-dependent transcription. 68 TLR signaling in its turn suppresses Gas6 and protein S expression via NFκB in macrophages. 69 Administration of recombinant Gas6 in a murine sepsis model, results in less mortality due to reduced neutrophil migration. 70 Another important anti-inflammatory mechanism is that TAM receptors enhance phagocytosis of apoptotic cells, also known as efferocytosis (Fig. 4) . 71 Gas6 and protein S bind to phosphatidylserine-positive moieties with their N-terminal GLA-domain (gammacarboxyglutamic domain). 9, 72, 73 The C-terminal binds to Mer on macrophages and Axl and Tyro3 on dendritic cells, 74 causing the intracellular kinase to phosphorylate. [75] [76] [77] Although the exact signaling cascades remain unknown, a variety of signaling molecules has been shown to be relevant, such as PI3K, phospholipase Cγ2, Src family kinases and interactions with the α vβ5 integrin. Rac1 is responsible for cytoskeletal rearrangement. 78, 79 Protection of the blood-brain barrier integrity also occurs through cytoskeletal rearrangement of brain endothelium by Rac1. It has been shown that this can be mediated by ligation of protein S to Tyro3, after which the protective sphingosine 1-phosphate receptor is activated. 80 Accumulated apoptotic cell debris that exists when efferocytosis is impaired, contains a variety of autoantigens that may cause lupus-like autoimmunity. Whether TAM receptors are involved in the etiology of lupus erythematosus remains unknown. An association between decreased protein S levels and SLE has been described, 81 whereas elevated Gas6 levels are associated with disease activity in SLE. 82 Mutations in the murine and human genes coding for Mer lead to impaired phagocytosis by retinal pigment epithelial cells. This leads to cumulation of photoreceptor outer segments and retinal degeneration, causing retinitis pigmentosa in humans. 83 It should be noted that this Mer-dependent signaling is mediated by both Gas6 and protein S as equally important ligands. 30 The TAM receptors do not mediate phagocytosis of bacteria, yeast or latex particles. 75, 84 However, viral entry into target cells is facilitated by Axl by apoptotic mimicry of the viral envelope. 85 Recently, new ligands for TAM receptor-mediated efferocytosis have been described:
Tubby, tubby-lke protein 1 (Tulp1) 86 and galectin-3. 87 Tubby and galectin-3 specifically bind to Mer, whereas Tulp1 can activate all three of the TAM receptors. Whether these new ligands can affect other mechanisms besides phagocytosis through TAM-activation, remains to be elucidated.
Knock-out mice
Single, dual and triple knock-out mice for the Tyro3/Axl/Mer receptors have been described extensively, as well as Gas6-deficient mice. Protein S knock-out mice however had not been described until recently. The various phenotypes, exhibited by the different knock-out mice, with effects on hemostasis, inflammation and other systems, are summarized in table 1. As can be seen in this table, knock-out mice for protein S, Gas6
and TAM receptors show a large variety of phenotypes. Protein S -/-mice have a lethal coagulopathy and vascular malformation. The latter is most probably due to the impaired blood flow caused by thrombi and -since the malformation is more severe than one would expect caused just by impaired blood flow -one could speculate it to be due to insufficient Axl signaling. However, protein S/Axl binding has never been determined.
Meanwhile, protein S has been shown to induce proliferation of vascular smooth muscle cells by receptor activation, a function known to be attributed to Axl when activated by Gas6. 88 Protein S knock-outs with cell-specific Cre drivers give new insights into protein S production: endothelial and hematopoietic cells produce 43% of the circulating protein S and local production of protein S in vascular smooth muscle cells is important for the vascular formation, as Sm22-Cre/protein S fl/fl knock-out mice show increased vascular permeability.
For 
Discussion
In this review of the literature, we have systematically explored the phenotypes of TAM/protein S/Gas6-deficient mice. Gas6, protein S and the TAM receptors have effects on primary hemostasis and coagulation, and they display an anti-inflammatory or a proinflammatory effect, depending on cell-type and even receptor. Besides describing these effects and their underlying mechanisms, the other goal of this review is to try hypothesize which functions of the TAM receptors are attributable to protein S. Because of the severe impairment of the haemostatic function in protein S knock-outs, it is difficult to assess the TAM-mediated effects in these mice. The disorders in vascular development seen, are too severe to only be caused by the coagulopathy. Although functional phenotypes in protein S-deficient mice may be hidden by redundant actions of Gas6, 30 the local synthesis of protein S seems to have a role in the vascular development. 89 Since mice lacking Axl suffer from similar underdeveloped blood vessels, this could imply locally produced protein S is required for activating Axl.
Since affinity between protein S and Axl has never been shown, it might be caused by protein S via a different mechanism than Axl activation. A recent study describes how protein S can inhibit VEGF-A-dependent EC migration, mitosis, and signaling via activation of Mer. 90 Although by this mechanism protein S deficient mice would have mice. This indicates that, in Gas6 knock-out mice, another ligand fulfills the inhibitory task within the immune system, possibly protein S. This concurs with the findings that protein S plays an equivalent role to Gas6 in the efferocytosis stimulated by the TAM receptors, 75 and that SLE patients may show lower protein S levels and/or anti-protein S antibodies. 88, 91 However, the newly described ligands Tubby, Tulp1 and Galectin-3 are also likely candidates that could explain this difference between the phenotypes.
The physiological role of Gas6 has been deducted mainly in GAS6 -/-mice, which are viable and able to reproduce. Until now no humans have been identified with a total Gas6 deficiency, so either Gas6 deficiency has no major clinical consequences in man, oralthough less probable -total Gas6 deficiency is not compatible with life in humans.
Unlike human protein S, human Gas6 is a high-affinity ligand for all human TAM receptors with K d in the nM range (reviewed by Hafizi 31 ). Redundancy with protein S in its function to activate Mer may actually mask important functions of Gas6, as has been demonstrated in the retina, in which locally produced protein S is as potent as Gas6 in activating Mer. 30 Therefore, much remains to be elucidated on protein S-mediated TAMreceptor activation.
Furthermore, certain molecular properties of the ligands require attention. The effect of multimerization of Gas6 and protein S on TAM receptor binding and activation is not completely clear. Upon purification, a major part of protein S is in a multimerized form with increased phospholipid binding properties. 92 Similar high molecular weight multimeres of protein S have been observed in plasma and reported to posses equal anticoagulant properties as the monomers. 93 It has been shown that membranes that contain phosphatidylserine serve as a scaffold for the auto-oxidation of Cys residues in protein S, which promotes the oligomerization of protein S that is required for Mer dependent apoptotic cell clearance. 73 This oligomerization may also provide a mechanism that allows the abundant protein S to activate Mer when necessary and not constitutively.
Whether oligomerization of protein S increases the affinity (single bond interaction) or the avidity (combined strength of multiple bond interactions) with TAM receptors is still to be determined, as well as whether murine protein S oligomerizes like human protein S.
Further research should be performed to elucidate when and how oligomerization is required for TAM-mediated functions of protein S and Gas6.
The importance of systemic circulating protein S to TAM receptor activation is unclear.
Complete deletion of protein S results in embryonic malformation and thrombosis in protein S knock-out mice. Furthermore, deletion of either hepatic or endothelial/hematopoietic production of protein S leads to ~50% reduction in systemic levels and fibrin formation in blood vessels. 89 Thus, it seems that to clarify the role of circulatory protein S as a TAM-receptor ligand, it will be necessary to generate an animal with mutant protein S, which only displays anticoagulant activity and no TAM receptor- • Death by coagulopathy with macroscopic blood clots and extensive hemorrhages between E15.5 and E17.5.
• Intravascular and interstitial fibrin depositions.
• Increased amounts of megakaryocytes in the liver, suggesting peripheral thrombocytopenia.
89,94
Not described • Vascular development is defective (caused by thrombosis and reduced protein Sdependent Axl signaling). 89 Protein S +/-
• 44% decrease in protein S levels.
• 53% decrease in APC cofactor activity.
• FVa based clotting time is shortened, thrombin generation is elevated, the lag time for thrombin generation is shortened.
Not described • Defects in vascular development.
89
Protein S -/-in hepatocytes (Alb-Cre/protein S fl/fl )
• 15% show fibrin depositions in blood vessels.
• 55% decrease in protein S levels.
• 47% decrease in APC cofactor activity. 89 
Not described Not described
Protein S -/-in endothelial and hematopoietic cells (tie2-Cre/ protein S fl/fl )
• Fibrin depositions in blood vessels (but less severe than in Alb-Cre/protein S1 fl/fl ).
• 43% decrease in protein S levels.
• 49% decrease in APC cofactor activity. 89 
Protein S -/-in vascular smooth muscle cells (Sm22-Cre/protein S fl/fl /Gas6 -/-)
• Vascular defects leading to permeation into liver parenchyma.
89

Gas6
-/-
• The mice are protected against venous and arterial thrombosis but do not display spontaneous bleeding (caused by platelet dysfunction).
38
• Reduced sequestration of platelets onto endothelium.
• Reduced thrombosis in models of endotoxinemia and vasculitis.
57
• Reduced expression and activity of tissue factor in vascular cells.
53
• Reduced inflammation and reduced myofibroblast activation in the steatotic liver, reducing liver fibrosis.
95
• Endothelial cells express less VCAM-1 and ICAM-1 when stimulated with TNF-α than WT.
• Reduced sequestration of platelets onto endothelium, of leukocytes onto endothelium and of platelets to leukocytes.
• Reduced leukocyte extravasation and inflammation in endotoxinemia, vasculitis and heart transplantation.
57
• More hypoxia-induced cell death and higher Il-1β and TNF-α expression in murine macrophages.
96
• More graft-versus-host disease when receiving liver transplantation.
97
• Less mortality and proteinuria in accelerated nephrotoxic nephritis than in WT mice.
64
• More stable atherosclerotic plaques by increased fibrosis and fewer macrophages.
98
• Elevated vascular permeability.
38
• Less oligodendrocytes and microglial activation after demyelination. • Recurrent thrombosis and hemorrhages in several tissues (including the brain), associated with the presence of antibodies to phospholipids as seen in auto-immune syndromes.
50
• Impaired hemostasis, thrombocytopenia due to platelet dysfunction and megakaryocytopoiesis.
100
• After ~4 weeks spleens and lymph nodes enlarge.
• After one year the spleens are about ten times the normal size.
• Hyperproliferation of constitutively activated B and Tcells (the latter slightly more).
• Ectopic lymphocytes in every researched organ.
• Clinical manifestations mimic autoimmune diseases similar to rheumatoid arthritis, pemphigus vulgaris and systemic lupus erythematosus.
• Spermatogenesis in males defected. • Reduced thrombus formation.
• Initial platelet aggregation is not reduced, but stabilization of the aggregates is, because of a decrease in outside-in signaling and platelet granule secretion. • Reduced thrombus formation.
• Initial platelet aggregation is not reduced, but stabilization of the aggregates is, because of a decrease in outside-in signaling and platelet granule secretion.
10
• Increase in apoptosis in response to flow reduction in carotid artery.
• Impaired vascular remodeling: Increase in CD45 + cells and decrease in VSMC, macrophages, and neutrophils. 101 • Enhanced inflammation in the CNS because of delayed removal of myelin debris during experimental autoimmune encephalomyelitis.
102
• Impaired vascular remodeling.
101
Mer kd or Mer -/-
• Reduced thrombus formation.
10,54
• Delayed cell clearance of infused apoptotic cells.
• Animals develop a SLE-like autoimmunity with antibodies to chromatin, DNA and IgG. 75, 103 • Mice show increased susceptibility and death in response to endotoxic shock.
• Monocytes stimulated with LPS express more NF-κB and produce more TNF-α.
11
• NKT cells have a defect in in-vivo GC-α stimulated production of IL-4 and IFN-γ.
62
• Enhanced B-cell responses in splenic marginal zone.
104
• Increased migration of macrophages, dendritic cells (DCs), plasmacytoid DCs, T cells, and B cells into the peritoneal cavity.
105
• Increased renal inflammation in nefrotoxic seruminduced nephritis.
65
• Decreased induction of c-Src and STAT3.
106
• 
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